General Medicine 2-Center for Systemic Amyloidosis and High-Complexity Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy.
Immunology and Transplantation Laboratory, Cell Factory, Pediatric Haematology Oncology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy.
Cells. 2024 Jan 29;13(3):254. doi: 10.3390/cells13030254.
We previously published that in patients with infantile hemangioma (IH) at the onset (T0) colony forming unit-fibroblasts (CFU-Fs) are present in in vitro cultures from PB. Herein, we characterize these CFU-Fs and investigate their potential role in IH pathogenesis, before and after propranolol therapy. The CFU-F phenotype (by flow cytometry), their differentiation capacity and ability to support angiogenesis (by in vitro cultures) and their gene expression (by RT-PCR) were evaluated. We found that CFU-Fs are actual circulating MSCs (cMSCs). In patients at T0, cMSCs had reduced adipogenic potential, supported the formation of tube-like structures in vitro and showed either inflammatory and ) or angiogenic () gene expression higher than that of cMSCs from CTRLs. In patients receiving one-year propranolol therapy, the cMSC differentiation in adipocytes improved, while their support in in vitro tube-like formation was lost; no difference was found between patient and CTRL cMSC gene expressions. In conclusion, in patients with IH at T0 the cMSC reduced adipogenic potential, their support in angiogenic activity and the inflammatory/angiogenic gene expression may fuel the tumor growth. One-year propranolol therapy modifies this picture, suggesting cMSCs as one of the drug targets.
我们之前发表过,在婴儿血管瘤(IH)患者发病初期(T0),PB 来源的体外培养物中存在成纤维细胞集落形成单位(CFU-F)。在此,我们对这些 CFU-F 进行了特征描述,并在普萘洛尔治疗前后研究了它们在 IH 发病机制中的潜在作用。通过流式细胞术评估 CFU-F 表型、分化能力和支持血管生成的能力(通过体外培养)及其基因表达(通过 RT-PCR)。我们发现 CFU-F 实际上是循环间充质干细胞(cMSCs)。在 T0 期患者中,cMSCs 的成脂潜能降低,在体外支持管状结构的形成,并且其炎症和血管生成基因表达高于对照(CTRL)的 cMSCs。在接受一年普萘洛尔治疗的患者中,cMSC 向脂肪细胞的分化得到改善,而其在体外管状形成中的支持作用丧失;患者和对照 cMSC 基因表达之间没有差异。总之,在 T0 期 IH 患者中,cMSC 降低了成脂潜能,它们对血管生成活性的支持以及炎症/血管生成基因表达可能促进肿瘤生长。一年的普萘洛尔治疗改变了这种情况,提示 cMSCs 是药物靶点之一。